The human papilloma virus (HPV) DNA test has higher sensitivity than cytology for cervical cancer screening. Therefore, cervical cancer cases that are missed by cytology could potentially be identified if we use primary HPV testing. Studies showed that HPV screening is the preferred primary test at age 35 and over. Given the high prevalence of harmless HPV infections, the use of HPV testing at younger age is less obvious. The number of cancers in young age is often mentioned to indicate the possible benefits of a more sensitive test. We actually estimated the proportion of those cases that is potentially preventable in The Netherlands by the use of a more sensitive screen-test at the first screening age 30, given that the more sensitive test is used at age 35 and over. We analysed the screening history of women diagnosed with cervical cancer in the period 2004 to March 2009, using data from the Dutch National Pathology Registry. Only 15-30% (two to four cases per 100,000 women) of the cases was preceded by negative cytology under age 35 and therefore could have been prevented by a more sensitive test at age 30. The lower the screening coverage and the shorter the screening interval in those screened at young age, the smaller the gain of a more sensitive test. So, as long as the current screening pattern is not changed, the majority of the cervical cancer cases at young age would still occur even when applying a more sensitive test at the younger ages.Mass screening for cervical cancer has been operational for women from age 30 years onwards in The Netherlands since 1996.1 Nevertheless, still approximately 700 women are diagnosed with cervical cancer annually in The Netherlands, of which 160 cases in the age group 30-39.2 Some of these cases were diagnosed based on symptoms while unscreened or were detected by their first screening moment.3 In these women, lack of screening test sensitivity did not play a role. However, some cases had screening but tested negative, 3 which might well be due to lack of sensitivity of, in the current situation, cytological screening. Meta-analyses and pooled analyses have established that human papilloma virus (HPV) DNA tests have higher sensitivity than cytology for detecting high grade, clinically relevant, cervical intraepithelial neoplasia (high grade CIN).4,5 Therefore, cervical cancer cases that are missed by cytology could have been identified if we had used primary HPV DNA testing as the primary screening test. Several studies showed that HPV screening is the preferred primary test at age 35 and over.6-12 HPV testing is less specific than cytology because it can detect harmless HPV infections. As these are considerably more prevalent in young women, the net benefits of using HPV testing under age 35 is less obvious. 13,14 Frequent screening at a young age detects many transient infections, cytological and histological abnormalities and every screening round adds to unnecessary triage, overdiagnosis and overtreatment as a consequence. Conversely, the number of life years gai...